FDA to Decide on Bydureon on Jan 28, 2012

The FDA is expected to make a decision Jan. 28 on the once-weekly diabetes drug Bydureon by Eli Lilly and Amylin. Amylin and its partners Eli Lilly and Co., and Alkermes, Inc., said the FDA has accepted their approval resubmission and set an action date of Jan. 28 for the drug Bydureon, the proposed brand name for the exenatide extended-release injectable treatment. It has already been approved in Europe. FDA